Medical school gift restriction policies linked to subsequent prescribing behavior

Doctors who graduate from medical schools with an active policy on restricting gifts from the pharmaceutical industry are less likely to prescribe new drugs over existing alternatives, suggests a study published in BMJ today.

Medical that restrict gifts to physicians from the pharmaceutical and device industries are becoming increasingly common, but the effect of such policies on physician prescribing behaviour after graduation into clinical practice is unknown.

So a team of US researchers set out to examine whether attending a with a gift restriction policy affected subsequent prescribing of three newly marketed psychotropic (, antidepressant, and antipsychotic) drugs.

They identified 14 US medical schools with an active gift restriction policy in place by 2004.

They then analysed prescribing patterns in 2008 and 2009 of physicians attending one of these 14 schools compared with physicians graduating from the same schools before the policy was implemented, as well as a control sample of 20 schools that only adopted a gift restriction policy in 2008.

For two of the three drugs examined, attending a medical school with an active gift restriction policy was associated with reduced prescribing of the new drug over older alternatives within the same drug class.

A significant effect was not seen for the third drug.

Among students who had a longer exposure to the policy, or were exposed to more stringent policies, prescribing rates were further reduced.

"Our findings suggest that policies, which have been increasingly adopted by medical schools since 2002, may have the potential to substantially impact clinical practice and reduce prescribing of newly marketed pharmaceuticals," say the authors.

They add: "Future research examining the effect of these policies on medications with varying levels of innovativeness is necessary to establish whether medical school gift restriction policies reduce prescribing of all newly marketed medications or affect prescribing selectively."

add to favorites email to friend print save as pdf

Related Stories

Thousands of patients prescribed high-risk drugs

Jun 22, 2011

Thousands of patients in Scotland who are particularly vulnerable to adverse drug events (ADEs) were prescribed high-risk medications by their GPs which could potentially cause them harm, according to research published in ...

Recommended for you

Express Scripts turns to AbbVie in huge hepatitis C deal

2 hours ago

The nation's largest pharmacy benefits manager is throwing its weight into a fight over the high cost of treating hepatitis C, saying it will cover a drug from AbbVie while pulling back on those from rival drugmakers.

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.